NTRK2 and neoplasm: Taken together, these data suggest that selective blockage of the BDNF/TRKB signaling pathway by a TRKB-specific inhibitor could selectively suppress cell proliferation, migration, and invasion of BDNFhigh/TRKBhigh PD-OSCC tumor cells.